Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment.
In 58 patients with progressive hormone-resistant metastatic cancer of the prostate, prostate-specific antigen (PSA) greater than 100 micrograms/l, haemoglobin less than 12.0 g/dl and pronounced fatigue were found to be independent adverse prognostic factors. These risk factors distinguished a subgroup of patients with a median survival of 9 months (none or only 1 risk factor present) from a subgroup with a median survival of 4 months (greater than or equal to 2 risk factors present). The clinician should be reluctant to enter patients from the second group into complicated and resource-demanding clinical studies, particularly if such trials require frequent and inconvenient follow-up examinations.
Fosså
S D
SD
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Paus
E
E
Lindegaard
M
M
Newling
D W
DW
D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D005221:Fatigue / Q000209:etiology; D006441:Hemoglobin A / Q000032:analysis; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods; D011379:Prognosis; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D000951:Antigens, Neoplasm; D006454:Hemoglobins; D006441:Hemoglobin A; D017430:Prostate-Specific Antigen